Aubagio® is indicated for the first line treatment of adult patients with relapsing remitting multiple sclerosis (MS).
|27/08/2013||20/09/2013||Full Pharmacoeconomic Evaluation recommended|
|25/11/2013||19/06/2014||Reimbursement Not Recommended|
The NCPE does not recommend reimbursement of teriflunomide (Aubagio®) at the current price.
The HSE has approved reimbursement following price negotiations.